Published in FEBS Lett on June 18, 1999
Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol (2011) 2.41
Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med (2008) 1.31
Single chain Fab (scFab) fragment. BMC Biotechnol (2007) 1.12
Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel (2008) 1.11
Bispecific antibodies and their applications. J Hematol Oncol (2015) 0.92
Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci (2003) 0.88
Antibody expressing pea seeds as fodder for prevention of gastrointestinal parasitic infections in chickens. BMC Biotechnol (2009) 0.88
Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation. Protein Eng Des Sel (2014) 0.87
The making of bispecific antibodies. MAbs (2017) 0.84
Design and applications of bispecific heterodimers: molecular imaging and beyond. Mol Pharm (2014) 0.78
A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Eng Des Sel (2015) 0.77
An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification. MAbs (2012) 0.76
Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy. Int J Mol Cell Med (2015) 0.76
Engineering tandem single-chain Fv as cell surface reporters with enhanced properties of fluorescence detection. Protein Eng Des Sel (2015) 0.75
Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface. Sci Rep (2016) 0.75
Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life. FEBS Open Bio (2016) 0.75
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL. Biomedicines (2017) 0.75
Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation. Biomedicines (2017) 0.75
Complete amino acid sequence of beta-tubulin from porcine brain. Proc Natl Acad Sci U S A (1981) 3.24
Complete amino acid sequence of alpha-tubulin from porcine brain. Proc Natl Acad Sci U S A (1981) 2.82
Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut (2008) 2.36
Use of the Pediatric Symptom Checklist to screen for psychosocial problems in pediatric primary care: a national feasibility study. Arch Pediatr Adolesc Med (1999) 2.23
Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res (1987) 2.22
Jellyfish responsible for Irukandji syndrome. QJM (2006) 2.18
Relationship between hunger and psychosocial functioning in low-income American children. J Am Acad Child Adolesc Psychiatry (1998) 2.00
Hunger in children in the United States: potential behavioral and emotional correlates. Pediatrics (1998) 1.99
Pressure immobilisation bandages in first-aid treatment of jellyfish envenomation: current recommendations reconsidered. Med J Aust (2001) 1.88
VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer (2008) 1.84
Differential expression of Ia and Ia-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma. J Immunol (1986) 1.82
Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem (1990) 1.77
CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol (1987) 1.76
Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J (1996) 1.74
Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein. Proc Natl Acad Sci U S A (1990) 1.72
Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res (2000) 1.72
A bacterial halidohydrolase. Its purification, some properties and its modification by specific amino acid reagents. Eur J Biochem (1971) 1.64
HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol (1986) 1.63
Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5'-nucleotidase (CD73). Tissue Antigens (1990) 1.57
The Pediatric Symptom Checklist. Support for a role in a managed care environment. Arch Pediatr Adolesc Med (1995) 1.48
Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer (1986) 1.48
T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor gamma delta + T cells. J Immunol (1991) 1.45
HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity (1997) 1.45
The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol (1988) 1.37
A surface expression vector for antibody screening. Gene (1991) 1.36
Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death Differ (1995) 1.32
Carboxy-terminal regions on the surface of tubulin and microtubules. Epitope locations of YOL1/34, DM1A and DM1B. J Mol Biol (1986) 1.31
Cooperation between carrier-reactive and hapten-sensitive cells in vitro. Nat New Biol (1971) 1.30
Glycoprotein incorporation and HIV-1 infectivity despite exchange of the gp160 membrane-spanning domain. Virology (1996) 1.29
Characterization of human lens major intrinsic protein structure. Invest Ophthalmol Vis Sci (2000) 1.28
RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc Natl Acad Sci U S A (1996) 1.27
Amplification of human B cell activation by a monoclonal antibody to the B cell-specific antigen CD22, Bp 130/140. J Immunol (1987) 1.27
Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med (1988) 1.25
Targeting recombinant antibodies to the surface of Escherichia coli: fusion to a peptidoglycan associated lipoprotein. Biotechnology (N Y) (1991) 1.24
High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J Immunol Methods (1997) 1.24
Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74). J Immunol (1991) 1.23
Carboxy-terminal amino acid sequence of alpha-tubulin from porcine brain. Nature (1979) 1.20
Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci U S A (1996) 1.20
Expression of the vertebrate Slit gene family and their putative receptors, the Robo genes, in the developing murine kidney. Mech Dev (2000) 1.20
Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. J Immunol (1988) 1.19
The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. Biochim Biophys Acta (1987) 1.17
Immediate effects of reversible HTLV-1 tax function: T-cell activation and apoptosis. Oncogene (1995) 1.16
In vivo induction of H-2K/D antigens by recombinant interferon-gamma. Eur J Immunol (1986) 1.15
Comparison of proteolytic cleavage patterns of alpha-tubulins and beta-tubulins from taxonomically distant species. J Mol Biol (1981) 1.15
Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis. J Pathol (2006) 1.14
The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene (2007) 1.14
Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Int J Cancer (1987) 1.13
Nurse practitioner/physician relationships. Am J Nurs (1980) 1.13
Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol (1989) 1.13
A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J (1998) 1.13
Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation. Blood (1987) 1.12
A risk assessment based approach to the management of acute poisoning. Emerg Med J (2006) 1.12
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol (1999) 1.11
Temporal and spatial transcriptional programs in murine kidney development. Physiol Genomics (2005) 1.11
Structural differences between brain beta 1- and beta 2-tubulins: implications for microtubule assembly and colchicine binding. EMBO J (1985) 1.11
Monoclonal antibodies to the rat liver glucocorticoid receptor. EMBO J (1982) 1.10
Invited commentary: is there a distinctively surgical ethics? Surgery (2001) 1.07
Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes. J Immunol Methods (1995) 1.07
Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br J Haematol (1999) 1.06
Dads and disomy and disease. Nature (1991) 1.05
Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation (2000) 1.05
The antigen-binding domain of a human IgG-anti-F(ab')2 autoantibody. Proc Natl Acad Sci U S A (1997) 1.04
An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling. Nat Genet (1996) 1.04
Identification of a second beta chain in pig brain tubulin. FEBS Lett (1979) 1.04
Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res (1991) 1.03
APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. Int Immunol (1995) 1.02
Amino acid sequence of alpha- and beta-tubulins from pig brain: heterogeneity and regional similarity to muscle proteins. Cold Spring Harb Symp Quant Biol (1982) 1.02
Arginase-1-expressing macrophages are dispensable for resistance to infection with the gastrointestinal helminth Trichuris muris. Parasite Immunol (2011) 1.00
Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Glycobiology (1999) 1.00
Of mice and men: hybridoma and recombinant antibodies. Immunol Today (2000) 1.00
Simultaneous mutagenesis of antibody CDR regions by overlap extension and PCR. Biotechniques (1994) 0.99
B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain. Int J Cancer (1987) 0.99
Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol (1998) 0.98
Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-Gamma. Int J Cancer (1985) 0.97
Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion. Protein Eng (1996) 0.96
Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng (1997) 0.96
A family of vectors for surface display and production of antibodies. Gene (1993) 0.96
Early detachment of colon carcinoma cells during CD95(APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. J Cell Biol (1996) 0.96
PAMAM structure-based multifunctional fluorescent conjugates for improved fluorescent labelling of biomacromolecules. Chemistry (2008) 0.94
Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. Bioconjug Chem (2008) 0.94
Monoclonal antibody Ki-B3 detects a formalin resistant antigen on normal and neoplastic B cells. Blood (1987) 0.93
The Wilms' tumour suppressor protein, WT1, undergoes CRM1-independent nucleocytoplasmic shuttling. FEBS Lett (2003) 0.92
A vector for the removal of deletion mutants from antibody libraries. Gene (1992) 0.92
CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion. Int Immunol (1991) 0.92
Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res (2000) 0.91
Antibodies to steroids from a small human naive IgM library. FEBS Lett (1997) 0.91
A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood (1999) 0.91
Life disruption and generic complexity: a social linguistic analysis of narratives of cancer illness. Soc Sci Med (2001) 0.91
Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood (1998) 0.91
A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity. Ther Immunol (1995) 0.90
Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J (2000) 0.90